Table 3 Prevalence of CV events among patients with cancer treated with the three antineoplastic monoclonal antibodies (N = 1,067)
CV Event | Total (N = 1067) | Trastuzumab (n = 626) | Bevacizumab (n = 418) | Pertuzumab combined with trastuzumab (n = 23) | p-value |
|---|---|---|---|---|---|
Overall CV events, n (%) | 174 (16.3%) | 77 (12.3%) | 89 (21.2%) | 8 (34.7%) |  < 0.001 |
Heart failure, n (%) | 50 (4.7%) | 46 (7.3%) | 3 (0.7%) | 1 (4.3%) |  < 0.001 |
Hypertension, n (%) | 60 (5.6%) | 16 (2.6%) | 38 (9.1%) | 6 (26.1%) |  < 0.001 |
Ischemic heart disease, n (%) | 2 (0.19%) | 1 (0.15%) | 1 (0.24%) | 0 | 0.940 |
Arrhythmias, n (%) | 4 (0.37%) | 2 (0.31%) | 2 (0.47%) | 0 | 0.880 |
Thromboembolism, n (%) | 32 (3%) | 4 (0.6%) | 27 (6.5%) | 1 (4.3%) |  < 0.001 |
Hemorrhage, n (%) | 26 (2.4%) | 8 (1.3%) | 18 (4.3%) | 0 | 0.006 |